Therefore, we expressed wild type Axin and mutants lacking p53 and/or β-catenin binding domains in lung cancer cell lines expressing wild type (A549) or mutant (BE1) p53 to delineate the mechanism by which Axin downregulates TCF-4 expression. This evidence concerns the gene TCF4 and lung carcinoma.